Hangzhou Tigermed Consulting Co., Ltd (3347.HK)
Helps drug and medical device companies run clinical trials and develop new medicines
38.56+0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-28.5%
The outlook
Tigermed is trading near the lower end of its 52-week range, with analyst consensus strongly bullish and an average price target around 36% above current levels. The stock shows mixed momentum against its moving averages, and carries a relatively high trailing P/E of 36.4. Overall sentiment leans bullish based on available data.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 12 analysts
Price trendMixed vs its moving averages
52-week range32% of the way from its 52-week low to high
Price targetAvg target +36% vs current price
Analyst price target
~12-month · 12 analysts52.40average target+35.9% vs now
Now 38.56
Low 28.70High 73.79
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$33.20B
52-wk high
60.60
52-wk low
28.12
50-day avg
34.03
200-day avg
41.49
Trailing P/E
36.4